VentureMed Group Announces It Is Now Doing Business as Flex Vascular
The DBA (Doing Business As) name reflects the company's focused commitment to vascular innovation and aligns directly with its flagship technology, the FLEX Vessel Prep™ System.
"Flex Vascular more clearly represents who we are and what we do," said
VentureMed Group, Inc. remains the company's legal corporate entity. The transition to operating as Flex Vascular is a branding update and does not involve a change in ownership, leadership, corporate structure, product offerings, or regulatory status.
The company's flagship product, the FLEX Vessel Prep™ System, remains unchanged. The device is FDA 510(k)-cleared and CE Mark-approved and is designed to optimize vessel preparation using proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology. Unlike traditional balloon-based approaches that apply static pressure, KEMIC leverages controlled motion and dynamic vessel apposition to create long, precise micro-incisions. This mechanism facilitates luminal gain, may enhance drug uptake when used in combination therapy, and may reduce vessel trauma with the goal of lowering the risk of restenosis.
Customers, partners, and stakeholders will begin seeing the Flex Vascular name across company communications, materials, and digital platforms. There is no impact to existing contracts, pricing, product availability, or customer support.
For more information, visit www.FlexVascular.com.
About Flex Vascular
Flex Vascular (VentureMed Group, Inc.) is a pioneering privately held medical device company based in
Media contact: Tom Michals
[email protected]
+1(763) 951-0280
View original content to download multimedia:https://www.prnewswire.com/news-releases/venturemed-group-announces-it-is-now-doing-business-as-flex-vascular-302705441.html
SOURCE FLEX Vascular
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Red Cross and NAACP announce new documentary honoring the father of blood banking, Dr. Charles R. Drew
- Form 8.5 (EPT/RI)-Gamma Communications Plc
- LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share